Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025ORX750 Phase 2a ...
MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG”, or the “Company”) announces the Company’s consolidated financial results for the year ended December 31, 2024. For details of the audited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback